bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figures 1-9 from Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression
Authors: Teicher Beverly A. , Polley Eric , Kunkel Mark , Evans David , Silvers Thomas , Delosh Rene , Laudeman Julie , Ogle Chad , Reinhart Russell , Selby Michael , Connelly John , Harris Erik , Monks Anne , Morris Joel
Published: April 2023

Supplemental Figure 1. SSX exon expression in 3 synovial sarcoma cell lines; Supplemental Figure 2. Multi-plate, multi-day validation assays run for the sacroma cell line screen; Supplemental Figure 3. IC50 heat map of the 236 compounds with an IC50 range of at least 1 log tested in the sarcoma lines; Supplemental Figure 4. Mean graph for expression of the miRs which correlate positively and negatively with response to the IGF1R kinase inhibitor linsitinib; Supplemental Figure 5. Heat maps for six PI3K kinase inhibitors, five Akt kinase inhibitors and five mTOR kinase inhibitors showing the IC50 response of the sarcoma lines, arranged by disease panel; Supplemental Figure 6. Mean graph for expression of the miRs which correlate positively and negatively with response to the PARP1 inhibitor BMN673; Supplemental Figure 7. A. Chemical structure of the IAP inhibitor birinapant. B. Heat map showing the IC50 response of the sarcoma lines, arranged by disease panel, for the IAP inhibitor birinapant; Supplemental Figure 8. Chart showing the birinapant log10 IC50s versus miR-204-5p expression illustrating that A-204 rhabdoid tumor line sensitivity to birinapant correlates positively with miR-204-5p expression; Supplemental Figure 9. A. Chemical structures of the kinase inhibitors WZ-4002, ZM-336372 and saracatinib. D. Heat map showing the IC50 response of the sarcoma lines, arranged by disease panel, for the kinase inhibitors WZ-4002, ZM-336372 and saracatinib.
Supplemental figure legends from Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression
Authors: Shang Zhiqun , Li Yanjun , Zhang Minghao , Tian Jing , Han Ruifa , Shyr Chih-Rong , Messing Edward , Yeh Shuyuan , Niu Yuanjie , Chang Chawnshang
Published: April 2023

Supplemental figure 1 ASC-J9® degraded androgen receptor expression in bladder cancer cells.Supplemental figure 2 HF or ASC-J9® induced THP-1 cell differentiating to M1 macrophage
Data Supplement from BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine
Authors: Jones Rebecca M. , Kotsantis Panagiotis , Stewart Grant S. , Groth Petra , Petermann Eva
Published: April 2023

Supplementary Materials and Methods and Supplementary Figures S1-S7: Figure S1: Cisplatin sensitivity of VC8 cells; Figure S2: Continud checkpoint signalling during replication restart; Figure S3: Additional pulse-field gel electrophoresis information; Figure S4: RAD51-dependent DSBs and cell death in pancreatic cancer cell line BxPC3; Figure S5: RAD51-dependent DSBs in ovarian cancer cell line OVCAR3; Figure S6: RAD51-dependent DSBs in ovarian cancer cell line MCF7; and Figure S7: DSB induction after release from Gemcitabine compared to continuous treatment.
Supplementary TableS1 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Clinico-pathologic characteristics
Supplementary figure legends from The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity
Authors: Chang Ki-Eun , Wei Bih-Rong , Madigan James P. , Hall Matthew D. , Simpson R. Mark , Zhuang Zhengping , Gottesman Michael M.
Published: April 2023

Supplementary figure legends
Supplementary Figure 3 from Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK Pathway and Epigenetic Regulation in Breast Cancer Cells
Authors: Shen Kaikai , Xie Jianling , Wang Hua , Zhang Hong , Yu Mengyuan , Lu Fangfang , Tan Hongsheng , Xu Hongxi
Published: April 2023

Supplementary Figure 3. Related to Fig. 4, cambogin-induced apoptosis was ROS-dependent in MDA-MB-468 and SK-BR-3 cells, similar to MCF-7 cells tested in Fig. 4.
Supplementary Figure 1 from Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK Pathway and Epigenetic Regulation in Breast Cancer Cells
Authors: Shen Kaikai , Xie Jianling , Wang Hua , Zhang Hong , Yu Mengyuan , Lu Fangfang , Tan Hongsheng , Xu Hongxi
Published: April 2023

Supplementary Figure 1. Related to Fig.1, cambogin markedly inhibited the proliferation and colongenicity, as well as induced apoptosis in MDA-MB-468 and SK-BR-3 cells in a time- and dose-dependent fashion, similar to MCF-7 cells tested in Fig. 1.
Supplementary Table 4 from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Table 4: Kinase inhibition/inhibitor toxicity association analysis for Group 3 cell lines.
Supplementary Table 2 from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Table 2: Comparison of mean EC50 values across Groups 1, 2, and 3 defined by hierarchical clustering.
Supplementary Figure S1 from Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
Authors: Kazim Sabiha , Malafa Mokenge P. , Coppola Domenico , Husain Kazim , Zibadi Sherma , Kashyap Trinayan , Crochiere Marsha , Landesman Yosef , Rashal Tami , Sullivan Daniel M. , Mahipal Amit
Published: April 2023

Supplementary Figure S1. Effect of KPT-330 on human normal pancreatic epithelial (HPNE) cell proliferation (MTT assay).
Supplementary Figures S1-S5 from The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis
Authors: Kiyonari Shinichi , Iimori Makoto , Matsuoka Kazuaki , Watanabe Sugiko , Morikawa-Ichinose Tomomi , Miura Daisuke , Niimi Shinichiro , Saeki Hiroshi , Tokunaga Eriko , Oki Eiji , Morita Masaru , Kadomatsu Kenji , Maehara Yoshihiko , Kitao Hiroyuki
Published: April 2023

Supplementary Figures S1-S5. Supplementary Figure S1: Structures of Pt-DNA adducts. Figure S2: Histogram of HCT116 p53+/+ cells treated with oxaliplatin or cisplatin. Figure S3: (A) p53 and p21 induction by oxaliplatin. (B) Identification of the mitochondria isoform of dUTPase (DUT-M). Figure S4. Related to Figure 4 A-C. Pri-miR-34a induction (A), downregulation of DUT transcript (B) and changes in the amount of proteins (C) by oxaliplatin. Figure S5. Related to Figure 5E. (A) Ectopic expression of TK1-3xFLAG, (B) Histogram of HCT116 p53+/+ cells with transient TK1-3xFLAG expression and oxaliplatin treatment.
Supplementary Figure 2 from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Figure 2: Promiscuous kinase inhibitors are more toxic to TNBC cell lines. Gini scores, which measure inhibitor selectivity and range from 0 (promiscuous) to 1 (perfectly selective), were previously calculated for the 180 kinase inhibitors. Box-and-whisker plots show the mean Gini scores for the upper (0.67) and lower (0.60) clusters of kinase inhibitors displayed in Figure 3. *p = 2.293 x 10-5.
Supplemental Table 2 from Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors
Authors: Dayekh Khalil , Johnson-Obaseki Stephanie , Corsten Martin , Villeneuve Patrick J. , Sekhon Harmanjatinder S. , Weberpals Johanne I. , Dimitroulakos Jim
Published: April 2023

Table of monensin induced genes in SCC25 cells identified by RNAseq analysis.
Supplemental Table 1 from Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors
Authors: Dayekh Khalil , Johnson-Obaseki Stephanie , Corsten Martin , Villeneuve Patrick J. , Sekhon Harmanjatinder S. , Weberpals Johanne I. , Dimitroulakos Jim
Published: April 2023

Table of agents that enhance either lovastatin or erlotinib cytotoxicity in HNSCC cells identified by screening a 1200 FDA approved compound library.
Data Supplement from Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46
Authors: Jungwirth Ute , Gojo Johannes , Tuder Theresa , Walko Gernot , Holcmann Martin , Schöfl Thomas , Nowikovsky Karin , Wilfinger Nastasia , Schoonhoven Sushilla , Kowol Christian R. , Lemmens-Gruber Rosa , Heffeter Petra , Keppler Bernhard K. , Berger Walter
Published: April 2023

Supplementary Video 1. Impact of calpain inhibition on the dynamics of KP64-induced rapid cell death of A427 cells
Supplemental Figure 5 from MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Authors: Xiao Yu , Nimmer Paul , Sheppard George S. , Bruncko Milan , Hessler Paul , Lu Xin , Roberts-Rapp Lisa , Pappano William N. , Elmore Steven W. , Souers Andrew J. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

Supplemental Figure 5: Flavopiridol synergizes with navitoclax in breast cancer cell lines in vitro.
Figure S3 from Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies
Authors: Calpe Silvia , Wagner Koen , El Khattabi Mohamed , Rutten Lucy , Zimberlin Cheryl , Dolk Edward , Verrips C. Theo , Medema Jan Paul , Spits Hergen , Krishnadath Kausilia K.
Published: April 2023

Specificity of VHHs to other BMPs (BMP9, BMP10 and BMP12) as well as other members of the TG-beta superfamily (such as TGF-beta and Activin-A).
Supplementary Tables 1 and 2 from Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer
Authors: Stintzing Sebastian , Zhang Wu , Heinemann Volker , Neureiter Daniel , Kemmerling Ralf , Kirchner Thomas , Jung Andreas , Folwaczny Matthias , Yang Dongyun , Ning Yan , Sebio Ana , Stremitzer Stefan , Sunakawa Yu , Matsusaka Satoshi , Yamauchi Shinichi , Loupakis Fotios , Cremolini Chiara , Falcone Alfredo , Lenz Heinz-Josef
Published: April 2023

Supplemental Tables giving detailed information about rs985374 genotypes and efficacy in FIRE-3
Supplementary Figure S1 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody
Authors: Zhang Zheng , Zhang Yang , Sun Qian , Feng Fei , Huhe Muren , Mi Li , Chen Zhinan
Published: April 2023

Supplementary Figure S1. Images of anti-tumor efficacy of Metuzumab in SCID mice bearing A549 (left) and NCI-H520 (right) human lung cancer cell line xenografts.
Supplementary Figure Legend from Elevated LIM Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation
Authors: Mardilovich Katerina , Gabrielsen Mads , McGarry Lynn , Orange Clare , Patel Rachana , Shanks Emma , Edwards Joanne , Olson Michael F.
Published: April 2023

Legend for Supplementary Figure 1
Supplementary Table S9 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Table S9. Comparison of dNSAF label-free quantitation values from chemical proteomics experiments in NSCLC cells with in vitro kinase assay parameters.
Supplementary Table S8 from Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Authors: Gridling Manuela , Ficarro Scott B. , Breitwieser Florian P. , Song Lanxi , Parapatics Katja , Colinge Jacques , Haura Eric B. , Marto Jarrod A. , Superti-Furga Giulio , Bennett Keiryn L. , Rix Uwe
Published: April 2023

Table S8. Pathway analysis of all identified phosphoproteins enriched by c-dasatinib and c-sunitinib affinity chromatography.
Supplementary Table S2 from Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Authors: Kwon Yeon-Jin , Petrie Kevin , Leibovitch Boris A. , Zeng Lei , Mezei Mihaly , Howell Louise , Gil Veronica , Christova Rossitza , Bansal Nidhi , Yang Shuai , Sharma Rajal , Ariztia Edgardo V. , Frankum Jessica , Brough Rachel , Sbirkov Yordan , Ashworth Alan , Lord Christopher J. , Zelent Arthur , Farias Eduardo , Zhou Ming-Ming , Waxman Samuel
Published: April 2023

Supplementary Table S2. List of genes with expression regulated by selamectin treatment
Supplementary Fig. 1 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Authors: Adelaiye Remi , Ciamporcero Eric , Miles Kiersten Marie , Sotomayor Paula , Bard Jonathan , Tsompana Maria , Conroy Dylan , Shen Li , Ramakrishnan Swathi , Ku Sheng-Yu , Orillion Ashley , Prey Joshua , Fetterly Gerald , Buck Michael , Chintala Sreenivasulu , Bjarnason Georg A. , Pili Roberto
Published: April 2023

Supplementary Fig. 1. Characterization of RP-R-01 and RP-R-02 PDX models
Supplementary Information from Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling
Authors: Dulong Sandrine , Ballesta Annabelle , Okyar Alper , Lévi Francis
Published: April 2023

The supplementary file reports the dynamic of nuclear TOP1 protein expression in Caco-2 cells (Figure S1), the circadian parameter values for clock and irinotecan metabolism gene mRNA expressions in synchronized Caco-2 cells (Table S1), the model-predicted circadian parameter values for the main metabolism proteins involved in irinotecan pharmacology (Table S2), the results of an experimental replication study of irinotecan chronoPK in synchronized Caco-2 cells (Figure S2). In addition, the 24- mean values and acrophases of mRNA expression rhythms in the current study are compared to those previously-published (Figure S3). Main irinotecan PK and PD parameters are also compared between both studies (Table S3).
Video 2. Time-lapse PI Imaging from Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer
Authors: Sato Kazuhide , Hanaoka Hirofumi , Watanabe Rira , Nakajima Takahito , Choyke Peter L. , Kobayashi Hisataka
Published: April 2023

Video 2. Time-lapse PI Imaging. Time-lapse sequential PI images (video) showed rapid membrane damage detected by PI staining after NIR light irradiation in cells treated with tra-IR700 (50 min observation). Flashing light is NIR light irradiation (2 J/cm2).(10sec interval, total 50min)
Supplementary Table S2 from Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma
Authors: Shirota Tomoki , Ojima Hidenori , Hiraoka Nobuyoshi , Shimada Kazuaki , Rokutan Hirofumi , Arai Yasuhito , Kanai Yae , Miyagawa Shinichi , Shibata Tatsuhiro
Published: April 2023

Multivariate analysis regarding to overall survival in EHCC.
Supplementary Figure 3 from Significance of Polypyrimidine Tract–Binding Protein 1 Expression in Colorectal Cancer
Authors: Takahashi Hidekazu , Nishimura Junichi , Kagawa Yoshinori , Kano Yoshihiro , Takahashi Yusuke , Wu Xin , Hiraki Masayuki , Hamabe Atsushi , Konno Masamitsu , Haraguchi Naotsugu , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Masaru , Mimori Koshi , Ishii Hideshi , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Correlation between MYC and PTBP1 levels in CRC. (A) qRT-PCR of clinical specimens. Expression of PTPB1 mRNA in the MYC mRNA high-expression group (n = 32) was significantly higher than in the MYC low-expression group (n = 32) (P = 0.018). (B) Western blot for PTBP1 protein levels in control RNA or siMYC of HCT116, DLD1, HT29, and SW480.
Supplementary Figure 1 from Significance of Polypyrimidine Tract–Binding Protein 1 Expression in Colorectal Cancer
Authors: Takahashi Hidekazu , Nishimura Junichi , Kagawa Yoshinori , Kano Yoshihiro , Takahashi Yusuke , Wu Xin , Hiraki Masayuki , Hamabe Atsushi , Konno Masamitsu , Haraguchi Naotsugu , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Masaru , Mimori Koshi , Ishii Hideshi , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

PTBP1 was preferentially overexpressed in CRC specimens. (A) qRT-PCR for PTBP1 mRNA levels in CRC specimens (n = 178) and corresponding normal mucosal specimens (n = 80). PTBP1 mRNA expression levels in CRCs were significantly higher than in normal samples. ***, significant difference, P < 0.0001. (B) Representative immunohistochemical analysis for PTBP1: (a) normal mucosa; (b) well-differentiated adenocarcinoma; (c) moderately differentiated adenocarcinoma; and (d) poorly differentiated adenocarcinoma. Scale bar: 100 ÃŽÂ¼m.
Supplemental Methods from Changes in BAI1 and Nestin Expression Are Prognostic Indicators for Survival and Metastases in Breast Cancer and Provide Opportunities for Dual Targeted Therapies
Authors: Meisen Walter Hans , Dubin Samuel , Sizemore Steven T. , Mathsyaraja Haritha , Thies Katie , Lehman Norman L. , Boyer Peter , Jaime-Ramirez Alena Cristina , Elder J. Bradley , Powell Kimerly , Chakravarti Arnab , Ostrowski Michael C. , Kaur Balveen
Published: April 2023

Description of western blot methodology for supplemental Figure and sources of gene expression data.
Supplementary Figure 1 from p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
Authors: Tentler John J. , Ionkina Anastasia A. , Tan Aik Choon , Newton Timothy P. , Pitts Todd M. , Glogowska Magdalena J. , Kabos Peter , Sartorius Carol A. , Sullivan Kelly D. , Espinosa Joaquin M. , Eckhardt S. Gail , Diamond Jennifer R.
Published: April 2023

Supplementary Figure 1. Treatment with MLN8237 induces markers of cellular senescence in two additional CAL-51 p53 and p73 shRNA knockdown clones (p53-12, p73-26).
Supplementary Figure Legends from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 5 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 5 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure 1 from Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Authors: Schlaepfer Isabel R. , Rider Leah , Rodrigues Lindsey Ulkus , Gijón Miguel A. , Pac Colton T. , Romero Lina , Cimic Adela , Sirintrapun S. Joseph , Glodé L. Michael , Eckel Robert H. , Cramer Scott D.
Published: April 2023

Supplementary figure 1: Epithelial and stromal marker expression in human prostate-derived patient-matched cells, BPH-1 and WPMY-1 cells. Supplements Figure 1.
Supplementary Figure 3 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 3 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Materials and Methods from Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
Authors: Dokter Wim , Ubink Ruud , van der Lee Miranda , van der Vleuten Monique , van Achterberg Tanja , Jacobs Danielle , Loosveld Eline , van den Dobbelsteen Diels , Egging David , Mattaar Ellen , Groothuis Patrick , Beusker Patrick , Coumans Ruud , Elgersma Ronald , Menge Wiro , Joosten John , Spijker Henri , Huijbregts Tijl , de Groot Vincent , Eppink Michel , de Roo Guy , Verheijden Gijs , Timmers Marco
Published: April 2023

Details are given of the synthesis of SYD983 and the non-binding control, preparation of fluorescently-labeled SYD983, bioanalysis of SYD983 using SEC, HIC, and RP-HPLC, functional assays like an ADCC assay and internalization, and details on the PK analysis of SYD983.
Supplementary Table 3 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Table 3: Functional analysis of genes significantly up- and down-regulated in SUP-B8 and NALM-6 cells.
Supplementary Table 1 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Table 1: Primers utilized for A687V EZH2 mutagenesis
Supplementary Figure 1 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Figure 1: Standard curves of recombinant modified histone proteins for quantification of western blots
Data Supplement from Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
Authors: Rossi Edmund A. , Rossi Diane L. , Cardillo Thomas M. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Methods for DNL conjugation of (E1)-3s and its biochemical characterization. These include SE-HPLC, LC-MS and Biacore methods.
Supplemental Figure 5 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 5. Effect of ENT on cell viability with 72 hour treatment
Data Supplement from Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
Authors: Rossi Edmund A. , Rossi Diane L. , Cardillo Thomas M. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Supplementary Figure S9. Induction of cytokine release by (19)-3s and 19-3 BiTE from PBMCs in the presence of Raji NHL cells. Results show the levels of TNF-α, IFN-γ and IL-6 after 20-h treatment with titrations of bsAb.
Supplementary Figure S8 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S8: Knockdown of Pdcd4 enhances OSI-906 induced phospho-P70S6K1
Supplemental Figure S3 from Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts
Authors: Kyle Alastair H. , Baker Jennifer H.E. , Gandolfo Maria-Jose , Reinsberg Stefan A. , Minchinton Andrew I.
Published: April 2023

Supplemental FIG S3 - Whole tissue section images comparing irinotecan extravasation versus MRI based contrast agent localization.
Supplementary Figure S4 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S4: Semi-quantitative analyses of the Western blot result of SW480 cells treated with OSI-906 in Fig. 3B
Data Supplement from Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
Authors: Zhang Yi-Xiang , Sicinska Ewa , Czaplinski Jeffrey T. , Remillard Stephen P. , Moss Samuel , Wang Yuchuan , Brain Christopher , Loo Alice , Snyder Eric L. , Demetri George D. , Kim Sunkyu , Kung Andrew L. , Wagner Andrew J.
Published: April 2023

Structure of NVP-LEE011
Table S1 from AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray
Authors: Alhakamy Nabil A. , Ishiguro Susumu , Uppalapati Deepthi , Berkland Cory J. , Tamura Masaaki
Published: April 2023

Table S1. Lung weight (mg) in LLC tumor-bearing mice
Supplementary Table S2 from TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Authors: Wheler Jennifer J. , Janku Filip , Naing Aung , Li Yali , Stephen Bettzy , Zinner Ralph , Subbiah Vivek , Fu Siqing , Karp Daniel , Falchook Gerald S. , Tsimberidou Apostolia M. , Piha-Paul Sarina , Anderson Roosevelt , Ke Danxia , Miller Vincent , Yelensky Roman , Lee J. Jack , Hong David , Kurzrock Razelle
Published: April 2023

Multivariate analysis of factors affecting treatment outcomes in 106 patients with TP53 molecular alterations versus 82 patient with TP53 wild-type, by individual factors of MDACC score vs MDACC score (only factors with p value< 0.02 in univariate were included in multivariate analysis)*
Supplementary figure 1 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
Authors: Lim Yangmi , Yoo Jiho , Kim Min-Soo , Hur Minkyu , Lee Eun Hee , Hur Hyung-Suk , Lee Jae-Chul , Lee Shi-Nai , Park Tae Wook , Lee Kyuhyun , Chang Ki Hwan , Kim Kuglae , Kang YingJin , Hong Kwang-Won , Kim Se-Ho , Kim Yeon-Gil , Yoon Yeup , Nam Do-Hyun , Yang Heekyoung , Kim Dong Geon , Cho Hyun-Soo , Won Jonghwa
Published: April 2023

Supplementary Figure 1. Kinetic binding interactions between GC1118 and EGFR as analyzed by SPR. SPR sensorgrams were obtained from injections of (A) GC1118 or (B) cetuximab over an EGFR-immobilized surface at a flow rate of 30 Âµl/min. The results of a quantitative evaluation of the experimental data are shown in Supplementary Table 2.
Supplementary Figure S4 from A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice
Authors: Feng Jia-Hua , Nakagawa-Goto Kyoko , Lee Kuo-Hsiung , Shyur Lie-Fen
Published: April 2023

Working model of DETD-35 in acquired vemurafenib resistance melanoma (A375-R) cells
Supplementary Figure S3: Western blot analysis of MAPK pathway inhibition by BI 847325 in NRAS-mutant cell lines. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
Authors: Sini Patrizia , Gürtler Ulrich , Zahn Stephan K. , Baumann Christoph , Rudolph Dorothea , Baumgartinger Rosa , Strauss Eva , Haslinger Christian , Tontsch-Grunt Ulrike , Waizenegger Irene C. , Solca Flavio , Bader Gerd , Zoephel Andreas , Treu Matthias , Reiser Ulrich , Garin-Chesa Pilar , Boehmelt Guido , Kraut Norbert , Quant Jens , Adolf Günther R.
Published: April 2023

(A), MEK1 and phospho-MEK1/2; (B) ERK1/2 and phospho-ERK1/2.
Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Authors: Beck Tim N. , Georgopoulos Rachel , Shagisultanova Elena I. , Sarcu David , Handorf Elizabeth A. , Dubyk Cara , Lango Miriam N. , Ridge John A. , Astsaturov Igor , Serebriiskii Ilya G. , Burtness Barbara A. , Mehra Ranee , Golemis Erica A.
Published: April 2023

TCGA datasets.
Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Authors: Beck Tim N. , Georgopoulos Rachel , Shagisultanova Elena I. , Sarcu David , Handorf Elizabeth A. , Dubyk Cara , Lango Miriam N. , Ridge John A. , Astsaturov Igor , Serebriiskii Ilya G. , Burtness Barbara A. , Mehra Ranee , Golemis Erica A.
Published: April 2023

Supplementary Table S1 (Excel file). TCGA datasets; Supplementary Table S2. CART cutoff points for each marker and the number of samples (N) in each category; Supplementary Table S3. Adjusted survival analysis; Supplementary Table S4. TCGA p16 expression data for HPV- and HPV+ HNSCC.
Supplementary Figure 2. Experiment that was used to select drug concentrations for combination screen. from An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Authors: O'Neil Jennifer , Benita Yair , Feldman Igor , Chenard Melissa , Roberts Brian , Liu Yaping , Li Jing , Kral Astrid , Lejnine Serguei , Loboda Andrey , Arthur William , Cristescu Razvan , Haines Brian B. , Winter Christopher , Zhang Theresa , Bloecher Andrew , Shumway Stuart D.
Published: April 2023

We ran 8 titration point curves (shown in gray) and then picked 4 concentration points that cover best the response curve for all cell lines (shown in red). The first point is the top plateau, the last is the bottom plateau and the other 2 are in between.
Supplementary Material from Acridine Derivatives as Inhibitors of the IRE1α–XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma
Authors: Jiang Dadi , Tam Arvin B. , Alagappan Muthuraman , Hay Michael P. , Gupta Aparna , Kozak Margaret M. , Solow-Cordero David E. , Lum Pek Y. , Denko Nicholas C. , Giaccia Amato J. , Le Quynh-Thu , Niwa Maho , Koong Albert C.
Published: April 2023

The Supplementary Material contains additional characterization for the compounds mentioned in the paper. We have provided melting point, 1H NMR and low resolution mass spectrometry data as well as HPLC purity for these known compounds. We have also provided a general synthetic method for the 9-amino acridine derivatives and detailed synthetic details and full characterization, including elemental analysis, for the new compound 10 (3,6-DMAD).
Supplementary Figure 2 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
Authors: Martinez-Font Esther , Felipe-Abrio Irene , Calabuig-Fariñas Silvia , Ramos Rafael , Terrasa Josefa , Vögler Oliver , Alemany Regina , Martín-Broto Javier , Obrador-Hevia Antònia
Published: April 2023

Supplementary Figure 2. Cell cycle and apoptosis analysis of STS cells after XAV939 and PKF118-310 treatment
Supplementary Tables S1-S4; Supplementary Figures S1-S5; and Supplementary Methods and Figure Legends from Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer
Authors: Zheng Ming-Wu , Zhang Chun-Hui , Chen Kai , Huang Mei , Li Ya-Ping , Lin Wan-Ting , Zhang Rong-Jie , Zhong Lei , Xiang Rong , Li Lin-Li , Liu Xin-Yu , Wei Yu-Quan , Yang Sheng-Yong
Published: April 2023

Table S1: Enzymatic activities of SKLB646 against recombinant human protein kinases, Related to Figure 1. Table S2: Inhibitory activities of SKLB646 or dasatinib against various TNBC cell lines together with characterizations of these cell lines, Related to Figure 1. Table S3: Inhibitory activities of SKLB646 against selected cancer cell lines and non-cancer cell lines, Related to Figure 1. Table S4: Pharmacokinetic parameters of SKLB646 in Sprague-Dawley rats, Related to Figure 6. Figure S1: A synthetic route for the target compound SKLB646, Related to Figure 1. Figure S2: The growth inhibition profile of HUVEC after treatment with different doses of SKLB646 or dasatinib for 72 hours, Related to Figure 4. Figure S3: Effects of SKLB646 treatment on weight of mice in human TNBC tumor xenografts models, Related to Figure 5. Figure S4: Quantitative analyses of the percentage of positive cells of Ki67 and C-CASP3 on tumor tissues of mice in human TNBC tumor xenograft models, Related to Figure 5. Figure S5: The proapoptosis effect of SKLB646 on tumor tissues of mice in human TNBC tumor xenograft models, Related to Figure 5. Supplementary Methods Supplementary Figure legends
Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
Authors: Ganesh Shanthi , Koser Martin L. , Cyr Wendy A. , Chopda Girish R. , Tao Junyan , Shui Xue , Ying Bo , Chen Dongyu , Pandya Purva , Chipumuro Edmond , Siddiquee Zakir , Craig Kevin , Lai Chengjung , Dudek Henryk , Monga Satdarshan P. , Wang Weimin , Brown Bob D. , Abrams Marc T.
Published: April 2023

Figure S1. Components of EnCore-A; Figure S2. Silencing of CTNNB1 mRNA after single-dose or multiple-dose regimens; Figure S3: Comparable activity achieved with a payload with 2'F modifications; Figure S4. Tumor growth inhibition in multiple subcutaneous xenograft models; Figure S5. No efficacy observed in APC/CTNNB1 wild-type RKO tumors; Figure S6. ApoE-independent DsiRNA delivery to primary and metastatic tumors; Figure S7. Detection of cleaved CTNNB1 mRNA by 5'RACE-Seq; Figure S8. EnCore-mediated delivery to CTNNB1/YAP-driven hepatoblastoma; Figure S9: Tolerability profile of EnCore-R/CTNNB1 DsiRNA in nonhuman primates.
Figure S1-S7 and Table S1 from ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus–Infected Cell Autophagic Death and Represses Tumor Growth
Authors: Dai Lu , Bai Aiping , Smith Charles D. , Rodriguez Paulo C. , Yu Fangyou , Qin Zhiqiang
Published: April 2023

Figure S1. KSHV infection up-regulates SphK2 expression from endothelial cells. Figure S2. ABC294640 significantly increases endogenous total ceramides/dh-ceramides from TIVE-LTC but not TIVE cells. Figure S3. Chloroquine effectively blocks autophagy induced by ABC294640 in TIVE-LTC cells. Figure S4. The top 2 scored (by the number of pathways) AN networks from 'common' gene sets altered within ABC294640-treated TIVE-LTC. Figure S5. ABC294640 causes G0/G1 cell cycle arrest in TIVE-LTC. Figure S6. Directly silencing of SphK2 by RNAi increases EGR1 expression in TIVE-LTC cells. Figure S7. Successful "knock-down" LC3B and Atg5 from TIVE-LTC cells. Table S1. Primer sequences for qRT-PCR.
Supplementary Figure S4. Oncolytic adenoviruses inhibit tumor growth, while trastuzumab transgene does not add to efficacy against HER2-negative breast cancer in vivo from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
Authors: Liikanen Ilkka , Tähtinen Siri , Guse Kilian , Gutmann Theresia , Savola Paula , Oksanen Minna , Kanerva Anna , Hemminki Akseli
Published: April 2023

3-4 week-old female nude/NMRI mice (Harlan Laboratories) were xenografted in both flanks with MDA-MB-436 triple-negative breast cancer cells (6Ã-106 cells/tumor). When tumors reached 5 mm in diameter, mice were randomized and treated intratumorally with 2Ã-109 VP of Ad5/3-Î"24 or Ad5/3-Î"24-tras, or mock-treated (PBS only) on indicated days, and tumor growth was monitored. Trastuzumab-coding Ad5/3-â^†24-tras virus treatment resulted in significant tumor-growth inhibition as compared mock (P<0.05), while Ad5/3-â^†24 was even more effective in this HER2-negative tumor model (P<0.001, vs. all), underlining the importance of antibody-mediated antitumor activities in HER2+ N87 model (Fig. 4). Tumor sizes indicated as percentage respective to day 0, which was set as 100%. Error bars represent SEM, n=6-8 tumors per group. ***,P<0.001; **,P<0.01; *,P<0.05; Mann Whitney test.
Supplementary Figure S3 from Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
Authors: Osman Abdullah A. , Monroe Marcus M. , Ortega Alves Marcus V. , Patel Ameeta A. , Katsonis Panagiotis , Fitzgerald Alison L. , Neskey David M. , Frederick Mitchell J. , Woo Sang Hyeok , Caulin Carlos , Hsu Teng-Kuei , McDonald Thomas O. , Kimmel Marek , Meyn Raymond E. , Lichtarge Olivier , Myers Jeffrey N.
Published: April 2023

The underlying synergy between cisplatin and MK-1775 in HNSCC is not mediated by apoptosis.
Supplementary Figure S2 from Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
Authors: Osman Abdullah A. , Monroe Marcus M. , Ortega Alves Marcus V. , Patel Ameeta A. , Katsonis Panagiotis , Fitzgerald Alison L. , Neskey David M. , Frederick Mitchell J. , Woo Sang Hyeok , Caulin Carlos , Hsu Teng-Kuei , McDonald Thomas O. , Kimmel Marek , Meyn Raymond E. , Lichtarge Olivier , Myers Jeffrey N.
Published: April 2023

Dual phospho-H3 staining for mitotic cells and PI flow cytometric analysis (FACS).
Supplemental Table 4 from Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Authors: Perera Timothy P.S. , Jovcheva Eleonora , Mevellec Laurence , Vialard Jorge , De Lange Desiree , Verhulst Tinne , Paulussen Caroline , Van De Ven Kelly , King Peter , Freyne Eddy , Rees David C. , Squires Matthew , Saxty Gordon , Page Martin , Murray Christopher W. , Gilissen Ron , Ward George , Thompson Neil T. , Newell David R. , Cheng Na , Xie Liang , Yang Jennifer , Platero Suso J. , Karkera Jayaprakash D. , Moy Christopher , Angibaud Patrick , Laquerre Sylvie , Lorenzi Matthew V.
Published: April 2023

Efficacy of JNJ-42756493 against human tumor xenograft models from different origins and FGFR alteration status. Mice bearing xenograft tumors (100-200mm3) were treated with 25mg/kg of JNJ-42756493 QD for indicated time and percent tumor growth inhibition (%TGI) compared to vehicle treated animal calculated at end of treatment.
Supplemental Table 3 from Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Authors: Perera Timothy P.S. , Jovcheva Eleonora , Mevellec Laurence , Vialard Jorge , De Lange Desiree , Verhulst Tinne , Paulussen Caroline , Van De Ven Kelly , King Peter , Freyne Eddy , Rees David C. , Squires Matthew , Saxty Gordon , Page Martin , Murray Christopher W. , Gilissen Ron , Ward George , Thompson Neil T. , Newell David R. , Cheng Na , Xie Liang , Yang Jennifer , Platero Suso J. , Karkera Jayaprakash D. , Moy Christopher , Angibaud Patrick , Laquerre Sylvie , Lorenzi Matthew V.
Published: April 2023

JNJ-42756493 anti-proliferative activity against cancer cells lines from multiple origins.. Detailed data supporting Figure 2.
Supplementary Movie S1 from Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Authors: Singha Netai C. , Nekoroski Tara , Zhao Chunmei , Symons Rebecca , Jiang Ping , Frost Gregory I. , Huang Zhongdong , Shepard H. Michael
Published: April 2023

HA depletion by PEGPH20 favors immune cell accessibility to HAhigh tumor cells.
Supplementary Figure S6 from Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Authors: Singha Netai C. , Nekoroski Tara , Zhao Chunmei , Symons Rebecca , Jiang Ping , Frost Gregory I. , Huang Zhongdong , Shepard H. Michael
Published: April 2023

Trastuzumab or NK cells specifically accumulate in HAhigh tumors.
Supplementary Figure 4 from Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics
Authors: Thomas Nisha E. , Thamkachy Reshma , Sivakumar Krishnankutty C. , Sreedevi Krishnakumar J. , Louis Xavier Lieben , Thomas Sannu A. , Kumar Rohith , Rajasekharan Kallikat N. , Cassimeris Lynne , Sengupta Suparna
Published: April 2023

PDF - 3082KB, Supplemental Fig S4: Number of Hydrogen bonds as a function of time.
Supplementary Table S1 from Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Authors: Ilmer Matthias , Garnier Agnès , Vykoukal Jody , Alt Eckhard , von Schweinitz Dietrich , Kappler Roland , Berger Michael
Published: April 2023

Primer sequences used for mRNA expression in human HB cells in this study.
Supplementary Figure S3 from Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Authors: Ilmer Matthias , Garnier Agnès , Vykoukal Jody , Alt Eckhard , von Schweinitz Dietrich , Kappler Roland , Berger Michael
Published: April 2023

(A) qRT-PCR on LGR5, AXIN2, and CTNNB1 of HepT1, HepG2, and HuH7: shown are the relative values of parental cells (black bars) in comparison to spheres: HepT1 in dark grey, HepG2 in light grey, and HuH7 in white.
Supplementary Figure 2 from A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
Authors: LaBonte Melissa J. , Yang Dongyun , Zhang Wu , Wilson Peter M. , Nagarwala Yasir M. , Koch Kevin M. , Briner Colleen , Kaneko Tomomi , Rha Sun-Young , Gladkov Oleg , Urba Susan G. , Sakaeva Dina , Pishvaian Michael J. , Hsieh Ruey-Kuen , Lee Wei-Ping , Lenz Heinz-Josef
Published: April 2023

Changes in tumor size relative to Week 6 lapatinib concentrations (ng/mL).
Supplemental Figure 6 from ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Authors: Mittapalli Rajendar K. , Chung Alexander H. , Parrish Karen E. , Crabtree Donna , Halvorson Kyle G. , Hu Guo , Elmquist William F. , Becher Oren J.
Published: April 2023

Elacridar does not significantly impact dasatinib delivery in absence of ABCG2 and ABCB1
Supplemental Figure 3 from ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Authors: Mittapalli Rajendar K. , Chung Alexander H. , Parrish Karen E. , Crabtree Donna , Halvorson Kyle G. , Hu Guo , Elmquist William F. , Becher Oren J.
Published: April 2023

Representative images of four dasatinib-treated murine brainstem gliomas in ABC KO and ABC WT mice (10X and 40X images).
Supplemental Figure 2 from ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Authors: Mittapalli Rajendar K. , Chung Alexander H. , Parrish Karen E. , Crabtree Donna , Halvorson Kyle G. , Hu Guo , Elmquist William F. , Becher Oren J.
Published: April 2023

Graph depicting fold change of Abcg2, Abcb1a, and Abcb1b transcripts of nestin-expressing brainstem progenitors, ABC KO tumor cell-lines, and ABC WT tumor cell-lines
Supplementary figure 2 from HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Authors: Court Karem A. , Hatakeyama Hiroto , Wu Sherry Y. , Lingegowda Mangala S. , Rodríguez-Aguayo Cristian , López-Berestein Gabriel , Ju-Seog Lee , Rinaldi Carlos , Juan Eduardo J. , Sood Anil K. , Torres-Lugo Madeline
Published: April 2023

S(A) HSPA6 siRNA gene knock down in vitro by quantitative real-time PCR. HSPA6 expression after gene knockdown in A2780cp20 and HeyA8 using HSPA6 siRNA. (B) Silencing of HSPA6 gene expression in HeyA8 tumor model after 72 hours of siRNA-DOPC injection (n=2). (C) Western Blot of HSP70 protein level in HeyA8 after 30 min MFH heat treatment at 41 and 43ËšC, with recovery time of 1, 4 and 6 hours
Supplementary figure S4 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Authors: Park Soon Young , Piao Yuji , Jeong Kang Jin , Dong Jianwen , de Groot John F.
Published: April 2023

TGF beta1 increases GSC invasion via POSTN.
Supplementary Figure 3 from High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer
Authors: Schouten Philip C. , Vollebergh Marieke A. , Opdam Mark , Jonkers Martijn , Loden Martin , Wesseling Jelle , Hauptmann Michael , Linn Sabine C.
Published: April 2023

Analysis of genomic loss of the 53BP1 locus by array comparative genomic hybridization
Supplemental Figure Legends from High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer
Authors: Schouten Philip C. , Vollebergh Marieke A. , Opdam Mark , Jonkers Martijn , Loden Martin , Wesseling Jelle , Hauptmann Michael , Linn Sabine C.
Published: April 2023

Supplemental Figure Legends
Supplemental Figure S6 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Authors: Tonsing-Carter Eva , Bailey Barbara J. , Saadatzadeh M. Reza , Ding Jixin , Wang Haiyan , Sinn Anthony L. , Peterman Kacie M. , Spragins Tiaishia K. , Silver Jayne M. , Sprouse Alyssa A. , Georgiadis Taxiarchis M. , Gunter T. Zachary , Long Eric C. , Minto Robert E. , Marchal Christophe C. , Batuello Christopher N. , Safa Ahmad R. , Hanenberg Helmut , Territo Paul R. , Sandusky George E. , Mayo Lindsey D. , Eischen Christine M. , Shannon Harlan E. , Pollok Karen E.
Published: April 2023

Single-agent or combination treatment does not affect TMD231 cell invasion.
Supplemental Figure S4 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Authors: Tonsing-Carter Eva , Bailey Barbara J. , Saadatzadeh M. Reza , Ding Jixin , Wang Haiyan , Sinn Anthony L. , Peterman Kacie M. , Spragins Tiaishia K. , Silver Jayne M. , Sprouse Alyssa A. , Georgiadis Taxiarchis M. , Gunter T. Zachary , Long Eric C. , Minto Robert E. , Marchal Christophe C. , Batuello Christopher N. , Safa Ahmad R. , Hanenberg Helmut , Territo Paul R. , Sandusky George E. , Mayo Lindsey D. , Eischen Christine M. , Shannon Harlan E. , Pollok Karen E.
Published: April 2023

Nutlin-3a does not affect mutant p53 stability in TMD231 cells following cycloheximide treatment.
Supplementary Table S2 from MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma
Authors: Filocamo Gessica , Brunetti Mirko , Colaceci Fabrizio , Sasso Romina , Tanori Mirella , Pasquali Emanuela , Alfonsi Romina , Mancuso Mariateresa , Saran Anna , Lahm Armin , Di Marcotullio Lucia , Steinkühler Christian , Pazzaglia Simonetta
Published: April 2023

List of genes differentially regulated relative to untreated control at the various time points and treatment conditions and summary of pathway enrichment analysis using GSEA.
Supplementary Figure S1 from MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma
Authors: Filocamo Gessica , Brunetti Mirko , Colaceci Fabrizio , Sasso Romina , Tanori Mirella , Pasquali Emanuela , Alfonsi Romina , Mancuso Mariateresa , Saran Anna , Lahm Armin , Di Marcotullio Lucia , Steinkühler Christian , Pazzaglia Simonetta
Published: April 2023

Chemical Structure and Molecular Data for MK-4101